UNSPSC 51434906: Amlodipine/benazepril

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434906 Amlodipine/benazepril is a Commodity code that encompasses supply of specific pharmaceutical products for use by state and local government agencies, primarily emergency medical services, health benefit programs, and public health systems. Recent solicitations show state and local governments procuring branded and generic cardiovascular medications, advanced life support drugs, and over-the-counter pharmaceuticals through a mix of single-award and multi-vendor cooperative purchasing arrangements. Issuing bodies include city fire and rescue departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS), and regional cooperative purchasing alliances serving multiple states and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). The work involves vendors supplying medications with specified National Drug Codes, maintaining expiration dates and shelf-life requirements, managing supply through authorized wholesalers, and complying with FDA regulations, Good Manufacturing Practices, and Drug Supply Chain Security Act documentation. Set-asides vary by issuing body—the City of Tampa applied a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount not to exceed $10,000; the Minnesota cooperative did not identify set-aside restrictions in available documentation.

Activity spans multiple states including Florida, Texas, and Minnesota with Oregon participating in the cooperative. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications (four drug line items totaling approximately 3,550 units) due April 8, 2026, with an estimated contract value of $40,000 and a one-year term plus two one-year renewal options and three 30-day extensions at the city's discretion. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—this was an exploratory information-gathering phase with no formal award timeline or budget stated. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with a contract term of two years effective July 1, 2026, covering participating state and local facilities across Minnesota and Oregon; vendors must work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and accept a 3 percent administrative fee on contract purchases.